Issued: Thursday 24 January 2013, London UK – LSE Announcement GlaxoSmithKline plc (LSE: GSK) today announced the appointment of Hans Wijers to its Board as a Non-Executive Director, effective 1st April 2013.The appointment is subject to shareholder …
Issued: Monday 28 January 2013, London UK and Mumbai/Hyderabad, India GlaxoSmithKline (GSK) and Biological E Limited (Biological E.), a leading Indian vaccines company, today announced an agreement to form a 50/50 joint venture (JV) for the early stage …
30 January 2013 Responding to a news article in The Guardian this morning on UK legal proceedings related toour type 2 diabetes medicine Avandia (rosiglitazone), we would like to make the following points: We have every sympathy for people with health …
Issued: Friday 1st February 2013, London UK GlaxoSmithKline plc. today announced the start of COMBI-AD, a Phase III study evaluating the combination of dabrafenib, its BRAF inhibitor and trametinib, its MEK inhibitor as adjuvant therapy for melanoma. This …
Issued: Tuesday 19 February 2013, London UK and South San Francisco, CA, USA GlaxoSmithKline plc (LSE:GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the New Drug Application (NDA) for the investigational once-daily LAMA/LABA combination …
Issued: Monday 16 July 2012, London UK GSK to acquire full ownership of BENLYSTA®, albiglutide and darapladib. Acquisition will be accretive to GSK core earnings in 2013. Tender offer amended to US$14.25 per share and extended until 27 July 2012 …
Issued: Monday 16 July 2012, London, UK GSK launches new advertising campaign to highlight the role that science will play in keeping the London 2012 Games clean GSK today marks its role as Official Laboratory Services Provider for the London 2012 …
Issued: Friday 13 July 2012, London UK Relvar™ and Breo™ proposed as brand names for FF/VI in EU and US; new dry powder inhaler proposed to be named Ellipta™ GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the submission of …
Issued: Thursday 12 July 2012, London UK GlaxoSmithKline plc announced today that it has withdrawn a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Tykerb (lapatinib) in combination with trastuzumab for the treatment …
Issued: Wednesday 11 July 2012, London UK GlaxoSmithKline (GSK) today announced that data have been received from the Phase III Harmony 8 study and from the event driven meta-analysis for assessment of cardiovascular safety conducted across the …
Issued: Wednesday 11 July 2012, London UK Shionogi-ViiV Healthcare LLC today announced that initial results have been received from the Phase III SINGLE (ING114467) study of the investigational integrase inhibitor dolutegravir in treatment-naïve adults …
Issued: Monday 02 July 2012, London UK & Philadelphia, US Final settlement of $3bn covered by existing legal provisions announced in November 2011. Fundamental changes to US compliance, marketing and selling procedures implemented in recent years. …
Issued: Monday 02 July 2012, London UK and South San Francisco, CA Headline results from the pivotal efficacy studies support intention to commence global filings for UMEC/VI from end of 2012, ahead of schedule GlaxoSmithKline plc (LSE: GSK) and …
Issued: Friday 29 June 2012, London UK - Expiration is after HGS process bid deadline of 16 July - Enables HGS shareholders to evaluate outcome of process and GSK’s offer GlaxoSmithKline plc (LSE: GSK) today announced it has extended its tender …
Issued: Friday 15 June 2012, London, UK GlaxoSmithKline plc (LSE: GSK) today confirmed that it has received a renewed invitation from Human Genome Sciences’ (NASDAQ: HGSI) to participate in its strategic alternatives review process which started in …
Issued: Thursday 14 June 2012, Philadelphia, Pennsylvania First combination vaccine to help prevent meningococcal serogroups C and Y and Hib disease GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved the …
Issued: Monday 11 June 2012, London UK – [For non US media only] Stiefel, a GSK company, today announced that it has entered into a worldwide agreement to acquire Toctino (alitretinoin) from Basilea Pharmaceutica Ltd. (Basilea). Toctino is a once-daily …
Issued: Saturday 09 June 2012, London UK Detailed 52 and 32-week data from the first two Phase III studies of the investigational once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist presented at ADA Detailed findings from a Phase III study …
Issued: Friday 08 June 2012, London UK GlaxoSmithKline plc (LSE: GSK) today announced it has extended its tender offer to acquire all of the outstanding shares of Human Genome Sciences (NASDAQ: HGSI) for US$13.00 per share in cash to 5:00 pm New York …
Issued: Thursday 07 June 2012, London UK and NC & Santa Clara, CA GlaxoSmithKline plc (GSK) and XenoPort, Inc. (Nasdaq: XNPT) announced today that the United States (US) Food and Drug Administration (FDA) has approved Horizant ® (gabapentin …
